Previous studies have predominantly explored FGF2 as a target within the FGF2/FGFR1 signaling pathway, employing exogenous FGF2 to facilitate breast cancer progression (Santolla et al., 2019). This evidence concerns the gene FGFR1 and breast carcinoma.